Literature DB >> 9697881

Lowering of p27Kip1 levels by its antisense or by development of resistance to 1,25-dihydroxyvitamin D3 reverses the G1 block but not differentiation of HL60 cells.

Q M Wang1, F Chen, X Luo, D C Moore, M Flanagan, G P Studzinski.   

Abstract

Cyclin-dependent kinase inhibitors are proteins with functions which appear to involve regulation of cell cycle traverse, and have been suggested to have a role in cell differentiation. However, there is as yet no rigorous proof that this is the case. We have addressed the participation of one of these inhibitors, p27Kip1, in the induction of differentiation and the subsequent G1 block induced in HL60 cells by 1,25-dihydroxyvitamin D3 (1,25D3). First, it was noted that sublines of HL60 cells able to grow rapidly in the presence of 1,25D3 have protein levels of p27Kip1 lower than the levels in cells subjected to 1,25D3-induced growth inhibition, but higher than in untreated parental cells. In contrast, there was no discernible relationship between the levels of p27Kip1 and the expression of differentiation markers. Further, HL60 cells treated with 1,25D3 and an oligonucleotide antisense, but not mismatched, to p27Kip1 showed an almost complete elimination of the 1,25D3-induced G1 block, but no decrease in the expression of differentiation markers. Similar results were obtained following transient transfection with an expression vector bearing the entire p27Kip1 coding sequence in the anti-sense orientation. This is the first direct demonstration that p27Kip1 plays a role in the 1,25D3-induced G1 arrest, and that partial reduction in its levels has no effect on the induction of differentiation in HL60 cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697881     DOI: 10.1038/sj.leu.2401088

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Authors:  Hagar Sharabani; Eugene Izumchenko; Qing Wang; Rita Kreinin; Michael Steiner; Zeev Barvish; Michael Kafka; Yoav Sharoni; Joseph Levy; Milan Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

2.  Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance.

Authors:  Xiangwen Chen-Deutsch; George P Studzinski
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

3.  Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEK/ERK module.

Authors:  Xuening Wang; George P Studzinski
Journal:  J Cell Physiol       Date:  2006-11       Impact factor: 6.384

4.  Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathway.

Authors:  Jing Zhang; Gary H Posner; Michael Danilenko; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-16       Impact factor: 4.292

Review 5.  Role of cell cycle regulatory molecules in retinoic acid- and vitamin D3-induced differentiation of acute myeloid leukaemia cells.

Authors:  X T Hu; K S Zuckerman
Journal:  Cell Prolif       Date:  2014-03-19       Impact factor: 6.831

Review 6.  Policing Cancer: Vitamin D Arrests the Cell Cycle.

Authors:  Sachin Bhoora; Rivak Punchoo
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

7.  Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications.

Authors:  H Gakiopoulou; P Korkolopoulou; G Levidou; I Thymara; A Saetta; C Piperi; N Givalos; I Vassilopoulos; K Ventouri; A Tsenga; A Bamias; M-A Dimopoulos; E Agapitos; E Patsouris
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.